Coltac Therapeutics
Preclinical Pharmaceutical Developing Bacteria-based Synthetic Positive Selection Screening System
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in January 2022, Coltac Therapeutics operates with 1–10 employees. The company has raised $5 million across two funding rounds from one investor.
Business overview
Coltac Therapeutics is a preclinical pharmaceutical company focused on drug discovery within the Health Tech & Life Sciences sector. The company develops and researches solutions for identifying molecular glues by leveraging its proprietary bacteria-based, synthetic positive selection screening system. Coltac Therapeutics primarily serves the biopharmaceutical and biotechnology industries, with a focus on oncology and drug discovery.
Company Intelligence Q&A
- What is Coltac Therapeutics' primary focus?
- Coltac Therapeutics specializes in preclinical pharmaceutical development, utilizing a bacteria-based, synthetic positive selection screening system to discover next-generation molecular glues.
- When was Coltac Therapeutics founded?
- Coltac Therapeutics was founded in January 2022.
- How much capital has Coltac Therapeutics raised?
- Coltac Therapeutics has raised a total of $5 million across two funding rounds.
- What industries does Coltac Therapeutics serve?
- Coltac Therapeutics serves the biopharmaceutical and biotechnology industries, with a particular focus on oncology and drug discovery.